Expand all sections

Siponimod

Extended indication SPMS; RRMS.
Therapeutic value No judgement

Product

Active substance Siponimod
Domain Neurological disorders
Main indication Multiple sclerosis
Extended indication SPMS; RRMS.
Manufacturer Novartis
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional remarks Werkingsmechanisme: 'Selective Sphingosine Phosphate Receptor'

Registration

Registration route Centralised (EMA)
Expected Registration 2019
Orphan drug No

Therapeutic value

Current treatment options Fingolimod en andere MS middelen.
Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

< 13,600

Market share is generally not included unless otherwise stated.
References Hersenstichting, Nationaal MS fonds.
Additional remarks Hersenstichting: In Nederland komt MS voor bij ongeveer 1 op de 1000 inwoners. Nederland telt dus ongeveer 17.000 mensen met MS. Nationaal MS fonds: Relapsing Remitting MS is de meest voorkomende beloopsvorm van MS en komt bij ongeveer 40% van alle mensen met MS voor. Ongeveer 40% van alle mensen met MS heeft de Secundair Progressieve MS variant. 80% van 17.000 is 13.600

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.